3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
17
Phase 1
6
Phase 1/2
5
Phase EARLY_PHASE1
2
Phase 3
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
149
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
47
Lymphoma, Large B-Cell, Diffuse
46
Leukemia
44
Lymphoma, Follicular
39
Lymphoma, Non-Hodgkin
35
Multiple Myeloma
33
Leukemia, Lymphocytic, Chronic, B-Cell
28
Leukemia, Myeloid, Acute
25
Burkitt Lymphoma
24
Neuroblastoma
21
Lymphoma, Large-Cell, Immunoblastic
16
Hodgkin Disease
16
Lymphoma, Mantle-Cell
14
Neoplasms
13
Triple Negative Breast Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
11
Sarcoma
10
Inflammatory Breast Neoplasms
10
Rhabdomyosarcoma
8
Recurrence
8
Neoplasms, Plasma Cell
8
Myelodysplastic Syndromes
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Graft vs Host Disease
8
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Biphenotypic, Acute
7
Lung Neoplasms
6
Interventions
Doxorubicin
3
10-propargyl-10-deazaaminopterin
3
Vincristine
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Gemcitabine
2
Drug Therapy
2
Cyclophosphamide
2
Alemtuzumab
2
romidepsin
1
cc-486
1
belinostat
1
Vitamin B 12
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Prednisone
1
Practice Guidelines as Topic
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Hematopoietic Stem Cell Mobilization
1
Folic Acid
1
Etoposide
1
Cytarabine
1
Cladribine
1
Carmustine
1
Busulfan
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell
×
Cyclophosphamide
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA
NCT00646854
2019-03-01
ACT-1
University of Aarhus
Phase 3
Completed
136 enrolled